TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Hutchmed (China) Limited
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

HUTCHMED has initiated the Phase III portion of a Phase II/III trial evaluating the combination of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine for treatment-naïve metastatic pancreatic ductal adenocarcinoma in China. Phase II results showed the combination achieved a median PFS of 7.20 months versus 5.52 months for chemotherapy alone, representing a 50.1% reduction in progression or death risk, with a favorable overall survival trend.

Insights
USBpS   neutral

Mentioned as a client of QuoteMedia with no specific performance details


HCM   positive

The company successfully advanced a promising combination therapy to Phase III based on Phase II data showing significant efficacy improvements (50.1% reduction in progression/death risk, higher ORR and DCR). The trial enrollment and positive clinical results support potential future regulatory approval and commercial opportunity in the large pancreatic cancer market.